Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. Most gastrointestinal stromal tumors (GISTs) express constitutively activated mutant isoforms of KIT or kinase platelet-derived growth factor receptor alpha (PDGFRA) that are potential therapeutic targets for imatinib mesylate. The relationship between mutations in these kinases and clinical response to imatinib was examined in a group of patients with advanced GIST. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Clinical Oncology Pubmed

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.


Abstract

Most gastrointestinal stromal tumors (GISTs) express constitutively activated mutant isoforms of KIT or kinase platelet-derived growth factor receptor alpha (PDGFRA) that are potential therapeutic targets for imatinib mesylate. The relationship between mutations in these kinases and clinical response to imatinib was examined in a group of patients with advanced GIST.

Loading next page...
 
/lp/pubmed/kinase-mutations-and-imatinib-response-in-patients-with-metastatic-Ci72EWBVaq

References (39)

ISSN
0732-183X
DOI
10.1200/JCO.2003.04.190
pmid
14645423
Publisher site
See Article on Publisher Site

Abstract

Most gastrointestinal stromal tumors (GISTs) express constitutively activated mutant isoforms of KIT or kinase platelet-derived growth factor receptor alpha (PDGFRA) that are potential therapeutic targets for imatinib mesylate. The relationship between mutations in these kinases and clinical response to imatinib was examined in a group of patients with advanced GIST.

Journal

Journal of Clinical OncologyPubmed

Published: Jan 5, 2004

There are no references for this article.